Who Should Not Take Semaglutide: Clinical Considerations

Last reviewed: June 2, 2026

Last updated: June 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide is not suitable for all patients. Absolute contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and pregnancy. Additional caution is warranted for patients with severe pancreatitis history, end-stage kidney disease, or hypersensitivity to semaglutide components.

Understanding who should avoid semaglutide—and why—is essential for safe, effective treatment planning. PlexusDx supports this evaluation by offering genetic insight into peptide metabolism pathways, helping patients and providers have more informed conversations about suitability and personalized alternatives.

Absolute Contraindications: When Semaglutide Must Be Avoided

Certain medical conditions eliminate semaglutide as a treatment option entirely. A personal history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 contraindicates semaglutide, as studies suggest GLP-1 agonists may increase C-cell proliferation. Pregnancy also requires discontinuation before conception.

Severe allergic reactions to semaglutide or its excipients warrant immediate avoidance. Patients with uncontrolled diabetic retinopathy may face additional risks. A qualified provider must review complete medical history and imaging records to rule out these conditions before initiating therapy.

Medical Conditions Requiring Careful Provider Review

Several diagnoses demand provider caution but not automatic exclusion. These include history of acute pancreatitis, severe kidney impairment, severe heart disease, and thyroid nodules. Dosing adjustments, enhanced monitoring, or alternative treatments may be necessary in these populations.

Condition	Clinical Consideration
Acute Pancreatitis History	Elevated risk of recurrence; GLP-1 may increase pancreatic enzymes; requires baseline assessment and monitoring
Severe Kidney Disease (eGFR <15)	Limited safety data; dose adjustment may be needed; risk of dehydration higher; close renal function tracking essential
Diabetic Retinopathy (Uncontrolled)	Rapid glycemic improvement may worsen vision acutely; baseline ophthalmology assessment recommended before initiation
Personal/Family Thyroid Cancer	Thyroid nodules require ultrasound evaluation; C-cell risk may be increased; may require alternative agent or enhanced surveillance

Medication Interactions and Gastrointestinal Considerations

Semaglutide slows gastric emptying, affecting absorption of oral medications. Patients taking drugs requiring rapid absorption—such as oral contraceptives, certain antibiotics, or anticoagulants—may need dosing schedule adjustments. A medication review with a pharmacist is essential before starting.

Patients with a personal history of severe gastrointestinal disorders, including inflammatory bowel disease or chronic pancreatitis, should discuss risks with their provider. Nausea, vomiting, and gastroparesis-like symptoms can occur and may be problematic in these populations.

Genetic Predispositions and Treatment Suitability: A New Framework

Emerging research suggests genetic variation in GLP-1 receptor signaling and metabolic pathways may influence both medication suitability and response. Variants in GLP1R, GIPR, and FTO genes can affect appetite regulation sensitivity and weight loss outcomes. Understanding your genetic profile may provide context for provider discussions about whether semaglutide is the right choice.

PlexusDx's Precision Peptide Genetic Test identifies predispositions in key peptide pathway genes, helping clarify individual metabolic patterns. This information should always be interpreted with a qualified healthcare provider and integrated with clinical assessment, not used to replace medical evaluation or guarantee outcomes.

How to Prepare for a Provider Consultation on Semaglutide Safety

Before discussing semaglutide with your provider, gather complete medical history: prior cancers, pancreatitis episodes, kidney or thyroid function tests, current medications, allergies, and family history of medullary thyroid cancer. This foundation ensures a thorough safety assessment and informed shared decision-making.

Consider requesting a baseline thyroid ultrasound and metabolic panel if you have risk factors. If genetic predispositions are part of your health evaluation, discuss how peptide pathway insights inform treatment planning. Your provider can then recommend semaglutide, an alternative GLP-1 agent, or a different approach entirely.

How PlexusDx Supports a More Personalized Approach

PlexusDx's genetic testing framework may help provide context for individual GLP-1 suitability by revealing predispositions in key metabolic pathways. Variants in GLP1R, GIPR, MC4R, and FTO genes can influence appetite response and weight loss trajectory. This information should be interpreted with a qualified healthcare provider to inform whether semaglutide aligns with your metabolic profile.

The Precision Peptide Genetic Test identifies predispositions—not guaranteed outcomes or exact medication response. Knowing your genetic profile in these pathways can support a more nuanced conversation with your provider about whether compounded semaglutide, tirzepatide, or another treatment is most likely to align with your individual biology.

When evaluating semaglutide suitability, genetic insight combined with clinical history creates a more complete picture. PlexusDx encourages patients to use this information as one piece of the decision-making puzzle, alongside traditional medical screening, to ensure safe and personalized treatment selection.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.